Head-To-Head Comparison: AquaBounty Technologies (NASDAQ:AQB) versus Compugen (NASDAQ:CGEN)

Compugen (NASDAQ:CGEN) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a summary of recent ratings for Compugen and AquaBounty Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1	0	3	1	2.80
AquaBounty Technologies	1	0	0	0	1.00

Compugen presently has a consensus price target of $5.00, indicating a potential upside of 110.08%. Given Compugen’s stronger consensus rating and higher possible upside, equities analysts clearly believe Compugen is more favorable than AquaBounty Technologies.

Volatility and Risk

Compugen has a beta of 2.76, meaning that its stock price is 176% more volatile than the S&P 500. Comparatively, AquaBounty Technologies has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500.

Insider and Institutional Ownership

12.2% of Compugen shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 1.0% of AquaBounty Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Compugen and AquaBounty Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
AquaBounty Technologies	N/A	-54.51%	-16.67%

Earnings and Valuation

This table compares Compugen and AquaBounty Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76 million	3.09	$35.34 million	$0.37	6.43
AquaBounty Technologies	$2.47 million	1.88	-$18.49 million	($1.19)	-0.76

Compugen has higher revenue and earnings than AquaBounty Technologies. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Summary

Compugen beats AquaBounty Technologies on 15 of the 15 factors compared between the two stocks.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

About AquaBounty Technologies

AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.